New studies show promise for Oxford’s Brainomix in US stroke networks

Brainomix, a developer of automated medical software for stroke image analysis, has presented new data from recent studies at an annual meeting of the US-based Society of Neurointerventional Surgery (SNIS).

The studies highlight the firm’s pioneering AI-driven technology, developed for the Brainomix 360 Stroke platform.

Cleared by the US Food and Drug Administration (FDA), the platform provides a real-time interpretation of brain scans to aid treatment and transfer decisions for stroke patients.

Brainomix is looking to help physicians to extract maximum value from non-contract CT scans.

Dr Michalis Papadakis, co-founder and CEO of Brainomix, said: “The studies presented this week at SNIS symbolize our ongoing commitment to scientific excellence, and reflect the successful partnerships that we’ve forged with leading academic institutions across the United States to jointly explore the frontiers of stroke AI imaging.

“Together, we’re identifying exciting opportunities that may expand the capabilities of physicians to better manage stroke patients across all levels of stroke networks with our technology.”

Dr Ansaar Rai at West Virginia University added: “The studies presented this week at SNIS highlight the clinical value of the Brainomix 360 Stroke platform, particularly relating to the e-ASPECTS and Triage Stroke algorithms that assess non-contrast CT scans, which are universally available to all stroke centres across the US.

“The results indicate that these algorithms generate clinically relevant results for frontline stroke physicians that could help them to better manage stroke patients eligible for mechanical thrombectomy across all centres within a network.”